328 related articles for article (PubMed ID: 29144754)
1. Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.
Fan Y; Kuai R; Xu Y; Ochyl LJ; Irvine DJ; Moon JJ
Nano Lett; 2017 Dec; 17(12):7387-7393. PubMed ID: 29144754
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
3. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
4. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
5. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
6. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
8. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Chen M; Xiang R; Wen Y; Xu G; Wang C; Luo S; Yin T; Wei X; Shao B; Liu N; Guo F; Li M; Zhang S; Li M; Ren K; Wang Y; Wei Y
Sci Rep; 2015 Sep; 5():14421. PubMed ID: 26394925
[TBL] [Abstract][Full Text] [Related]
9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
10. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
Tanaka H; Shimizu K; Hayashi T; Shu S
Cell Immunol; 2002 Nov; 220(1):1-12. PubMed ID: 12718934
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
Llopiz D; Ruiz M; Silva L; Repáraz D; Aparicio B; Egea J; Lasarte JJ; Redin E; Calvo A; Angel M; Berzofsky JA; Stroncek D; Sarobe P
Cancer Lett; 2021 Feb; 499():279-289. PubMed ID: 33232788
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
15. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
18. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
19. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
[TBL] [Abstract][Full Text] [Related]
20. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
